Physician profile
Joshua C James
NPI 1154503308
$2,598.47
in general payments reported to CMS, 2019-2025
13 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Otolaryngic Allergy provider received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $254 · 2021: $207 · 2022: $96.07 · 2023: $1,039 · 2024: $129 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688 · Travel and Lodging: $558 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.91 |
| Travel and Lodging | $557.89 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $661.70 | 2023-2025 | Inspire |
| Medical Device Business Services, INC. | $400.00 | 2023 | |
| Acclarent, INC | $397.07 | 2019-2023 | Trudi Nav Cable |
| Stryker Corporation | $308.75 | 2019-2022 | |
| Aerin Medical INC. | $197.88 | 2019-2025 | |
| Integra Lifesciences Corporation | $193.70 | 2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Genzyme Corporation | $126.50 | 2024-2025 | |
| Neurent Medical Limited | $119.42 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Intersect Ent, INC. | $90.74 | 2019-2020 | |
| Medtronic, INC. | $49.34 | 2024 | Propel |
| Cochlear Americas | $21.89 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.79 | 2023 | Dupixent |
| Olympus America INC. | $12.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.